Company intelligence / Profile preview
Abbisko Therapeutics
Shanghai, Shanghai, Chinaabbisko.com ↗
- Ownership
- Public · 2256.HK
- Development stage
- Phase 3
01
Overview
The company has multiple programs in clinical development, with pimicotinib (CSF-1R antagonist) in Phase 3 for Pigmented Villonodular Synovitis, fexagratinib (FGFR1/2/3 antagonist) in Phase 1/2, and several other candidates in Phase 1.
- Therapeutic areas
- OncologyRheumatology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
03
Partnerships
Merck KGaA (commercialization agreement for pimicotinib)
04
Financials
- Market cap
- $582M
- Total revenue
- $89.4M
- Enterprise value
- $291.4M
Beyond the preview
Go deeper on Abbisko Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abbisko Therapeutics.